Cutoff level of prostate volume to predict the efficacy of α1-D/A adrenoceptor antagonist, naftopidil

Yasushi Tanuma, Yoshinori Tanaka¹, Tomoshi Okamoto²
Department of Urology, Hokkaido Social Welfare Association Hakodate Hospital, ¹Department of Urology, Hokkaido Prefectural Esashi Hospital, Hokkaido, ²Okamoto Urology Clinic, Hokuto, Japan

Abstract

Introduction: In lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) patients, prostate volume (PV) at baseline affects the improvement of International Prostate Symptom Score (IPSS) by naftopidil (NAF), but not total IPSS (IPSS-TS). To predict the efficacy of NAF, the PV cutoff point was examined using IPSS-VS.

Materials and Methods: Seventy-seven patients with LUTS/BPH were administrated with NAF 50 mg/day for 4 weeks. Age, PV, IPSS, IPSS quality-of-life (IPSS-QoL), and maximum flow rate (MFR) were evaluated at baseline, and IPSS, IPSS-QoL, and MFR were evaluated after the treatment (at 4 weeks). Responders and nonresponders were divided by IPSS-VS at 4 weeks, and the PV cutoff point was calculated.

Results: At baseline, the mean age and PV were 70.7 ± 8.2 years (range, 54–88 years) and 43.3 ± 24.5 mL (range, 20.6–141.7 mL), respectively. After 4 weeks, area under the receiver operating characteristic curve was largest in the patients with <4 points of IPSS-VS. The best standard value to evaluate the efficacy IPSS-VS at 4 weeks was 4 points for the NAF treatment, and the best PV cutoff point was 37.3 mL (sensitivity 60.5%, specificity 71.9%).

Conclusions: PV at baseline was one of the predictive factors which affected the efficacy of NAF for IPSS-VS, and LUTS/BPH patients who had PV more than 37.3 mL indicated poor improvement of IPSS-VS, even if IPSS-TS was improved.

Keywords: Benign prostatic hyperplasia, lower urinary tract symptom, naftopidil

INTRODUCTION

Prostate volume (PV) at baseline affected the long-term outcome with the treatment of α1-adrenoceptor antagonist (α1-blocker; α1-B) in lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) patients.[1-6] PV is seemed to be a predictive factor to affect the short-term efficacy of International Prostate Symptom Score (IPSS) in naftopidil (NAF) treatment (50 mg/day for 4 weeks).[7] However, the PV cutoff point, which can predict the short-term efficacy of IPSS-VS, is unknown in the NAF treatment.

Hence, we examined the PV cutoff point at baseline that could predict the efficacy of NAF using IPSS-VS.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

How to cite this article: Tanuma Y, Tanaka Y, Okamoto T. Cutoff level of prostate volume to predict the efficacy of α1-D/A adrenoceptor antagonist, naftopidil. Urol Ann 2021;13:296-300.
MATERIALS AND METHODS

The present study was conducted retrospectively, and 77 patients were enrolled by the hospital or clinic who participated in this study from July 2008 to February 2014, and all patients were given NAF 50 mg/day for 4 weeks. The inclusion criteria were the patients with a clinical diagnosis of LUTS/BPH together with age ≥50 years, PV ≥20 mL, total IPSS (IPSS-TS) ≥8, and IPSS quality-of-life (IPSS-QoL) ≥3. The following patients were excluded: prostatic cancer, bladder outlet obstruction (BOO), disease activity across multiple organs suspected serious conditions, comprehension difficulties, or serious conditions receiving α1-B for hypertension. Patients judged by the attending physician to be inappropriate were also excluded. Age and PV were evaluated at the start of treatment (baseline). IPSS, IPSS-QoL, voided volume (VV), maximum flow rate (MFR), and postvoid residual urine volume (PVR) were evaluated at baseline and 4 weeks.

For the statistical comparison between the baseline and 4 weeks, IPSS-TS, IPSS storage symptoms (IPSS-SS), IPSS-VS, and IPSS-QoL were analyzed using Wilcoxon signed-rank test, whereas VV, MFR and PVR were compared using paired t-test. The comparison between groups for PV, MFR and PVR were analyzed using Student’s t-test, and others were done using Mann–Whitney U-test.

The correlation and regression of IPSS-VS at 4 weeks and change in IPSS-TS from the baseline to 4 weeks were analyzed using Spearman’s rank correlation coefficient. For estimation of the PV cutoff point, the best standard value of IPSS-VS at 4 weeks was calculated using area under the receiver operating characteristic (ROC) curve. The sensitivity and specificity of PV cutoff point were evaluated using the ROC curve. The continuous values were summarized as mean ± standard deviation. All analyses were performed by SPSS version 22 (IBM Japan, Tokyo, Japan) with the two tailed, and P < 0.05 was considered statistical significance.

This study was approved by the institutional review board of Hokkaido Social Welfare Association Hakodate Hospital and obtained all participants’ consent.

RESULTS

Of the 77 patients who were enrolled, six patients did not visit after 4 weeks and one patient was noncompliance. Accordingly, PV cutoff point was analyzed in a total of 70 patients. Baseline characteristics, change in subjective symptoms, and objective findings are shown in Table 1. Mean age and PV were 70.7 ± 8.2 years (range, 54–88 years) and 43.3 ± 24.5 mL (range, 20.6–141.7 mL), respectively.

IPSS-TS, IPSS-SS, IPSS-VS, and IPSS-QoL at 4 weeks were significantly improved as compared to the baseline; however, the changes of VV, MFR, and PVR were not statistical significance.

In the AUA guidelines, α1-Bs improve IPSS-TS by 4–6 points on an average.[6] Therefore, we presumed IPSS-VS at 4 weeks equivalent to the 4–6 points reduction in IPSS-TS from the baseline (ΔIPSS-TS). As shown in Table 2, IPSS-VS at 4 weeks and Δ IPSS-TS were significantly correlated (ρ = 0.476, P < 0.001). The regression equation is shown below:

IPSS-VS at 4 weeks = 0.2896 × ΔIPSS-TS + 6.2671.

At 4 weeks, IPSS-VS, which is equivalent to decrease of IPSS-TS (less than 4 points), was calculated according to the regression equation, and it was estimated to be less than 5.1 points.

Table 1: Baseline characteristics and changes in subjective symptoms and objective findings (n=70)

|                          | Baseline | 4 weeks | P     |
|--------------------------|----------|---------|-------|
| Age (years)              | 70.7±8.2 | -       | -     |
| PV (mL)                  | 43.3±24.5| -       | -     |
| Total IPSS (IPSS-TS)     | 16.5±5.8 | 11.8±6.6 | <0.001|
| IPSS-SS                  | 7.3±2.6  | 5.3±2.8 | <0.001|
| IPSS-VS                  | 6.9±4.3  | 4.9±3.9 | 0.001 |
| IPSS-QoL                 | 4.7±1.0  | 3.2±1.6 | <0.001|
| VV (mL)                  | 166.4±113.0 | 160.2±90.3 | NS   |
| MFR (mL/s)               | 12.0±7.7 | 11.4±7.7 | NS   |
| PVR (mL)                 | 62.5±69.2 | 62.9±86.1 | NS   |

Statistical analysis was performed with paired t-test (VV, MFR, and PVR) and Wilcoxon signed-rank test (for others). P < 0.05 was considered as statistical significance. IPSS: International Prostate Symptom Score, SS: Storage symptoms score (frequency, urgency, and nocturia), VS: Voiding symptoms score (intermittency, weak stream, and straining), QoL: Quality of life, PV: Prostate volume, VV: Voided volume, MFR: Maximum flow rate, PVR: Postvoid residual urine volume, NS: Not significance.

Table 2: International Prostate Symptom Score voiding symptoms at 4 weeks which was estimated by the equation

| Change in ΔIPSS-TS | Estimated IPSS-VS at 4 weeks |
|--------------------|------------------------------|
| -4                 | 5.1                          |
| -5                 | 4.8                          |
| -6                 | 4.5                          |
| -7                 | 4.2                          |
| -8                 | 4.0                          |
| -9                 | 3.7                          |

Regression equation: IPSS-VS at 4 weeks=0.2896×(ΔIPSS-TS)+6.2671

ΔIPSS-TS: Change in IPSS-TS from the baseline to 4 weeks.
IPSS: International Prostate Symptom Score, TS: Total score, VS: Voiding symptoms score (intermittency, weak stream, and straining)
As shown in Table 3, Area under the ROC curve (Az) was the largest in the patients with 4 points or less of IPSS-VS at 4 weeks. ROC curve was plotted to examine the PV cutoff point [Figure 1]. The PV cutoff point which evaluated the efficacy of NAF using IPSS-VS was 37.3 mL (sensitivity 60.5%, specificity 71.9%).

In the patients who had >37.3 mL of PV (Group large) and <37.3 mL (Group small), the efficacy of NAF is shown in Table 4. All IPSS-TS, IPSS-SS, and IPSS-VS at 4 weeks were significantly improved compared with the baseline in the Group small, whereas in the Group large, only IPSS-TS and IPSS-SS were improved significantly.

**DISCUSSION**

In the previous investigations, PV at baseline affected the long-term outcome with the treatment of α1-B in LUTS/BPH patients. The European Association of Urology guidelines show that pressure flow study is useful in the diagnosis of lower urinary tract (including bladder) functions. However, it is an invasive and serious burden for LUTS/BPH patients. If the prediction is not invasive in the efficacy, the procedure must be convenient for the patients. If a predictive factor of the efficacy is noninvasive, it must be convenient for the patients.

In the long-term pharmacotherapy, BOO often generates a treatment failure. Ultrasonography declared PV or intravesical prostatic protrusion (IPP) was the predictive factor of BOO. According to a multivariate logistic regression analysis, IPP is a better predictive factor of BOO in comparison with PV, whereas Kim et al. showed that PV was the most important independent noninvasive predictive factor of BOO, among PV, Qmax, and PVR. Trumbeckas et al. showed that average/peak flow rate combined with PV could be used for the prediction of BOO. Therefore, we thought that PV might be evaluated with one of predictive factors of BOO.

Conversely, it was reported that PV is negatively a predictive factor of the treatment failure in the short-term α1-B dosing. However, IPSS-TS was improved by tamsulosin for 16 weeks in the patients with large PV as
Tanuma, et al.: PV cutoff level to predict efficacy

In the present study, PV cutoff point was able to evaluate the efficacy of 4 weeks NAF 50 mg/day treatment using IPSS-VS. As the result, IPSS-VS at 4 weeks can potentially evaluate improvement of subjective symptoms, because IPSS-VS at 4 weeks and Δ IPSS-TS were significantly correlated, and the best PV cutoff point was 37.3 mL when the patients with less than 4 points of IPSS-VS at 4 weeks were defined as effective.

However, the significantly PV cutoff point was not able to find when IPSS-TS or IPSS-SS was used as a parameter of the efficacy (data not shown). The patients with less than 37.3 mL of PV significantly improved IPSS-VS at 4 weeks in comparison with the patients who had more than 37.3 mL, whereas improvement of IPSS-TS and IPSS-SS was similar in both subgroups. Therefore, the PV cutoff point of 37.3 mL is likely appropriate in the present study. These results are supported by the previous investigation by Hong et al., who showed that predictive factors which affect the efficacy of the therapy were PV and IPSS at baseline, and the best cutoff point of the PV and IPSS was 35.65 mL and 23.5 points, respectively. Moreover, in the previous studies in the different groups, the values of PV of the nonresponders by naftopidil treatment were 35.1 and 36.7 mL, respectively.

In the present study, there were several limitations that the cutoff point of IPP was not presented. The statistical analyses were post hoc analysis and small sample size. Therefore, the prospective study on the predictive factors in short-term efficacy of α1-B treatment is needed, particularly using easy measurement and subjective symptoms.

CONCLUSION

IPSS-VS at 4 weeks is able to evaluate the improvement of subjective symptoms. Moreover, in the patients with more than 37.3 mL of the baseline PV, the voiding symptoms were likely to poor improvement even if subjective symptoms were significantly improved. These results are informative to reconsider the treatment strategy in LUTS/BPH patients who were given NAF for 4 weeks.

Financial support and sponsorship

Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES

1. de la Rosette JJ, Kortmann BB, Rossi C, Sonke GS, Floratos DI, Kiemeney LA. Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. J Urol 2002;167:1734-9.
2. Hong SJ, Ko-WJ, Kim SI, Chung BH. Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia: An observational cohort study. Eur Urol 2003;44:94-9.
3. Masumori N, Hashimoto J, Itoh N, Tsukamoto T, The Sapporo Medical University Naftopidil Study Group. Short-term efficacy and long-term compliance/treatment failure of the alpha1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Scand J Urol Nephrol 2007;41:422-9.
4. Masumori N, Tsukamoto T, Horita H, Sunaoshi K, Tanaka Y, Takeyama K, et al. α1-blocker tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5-year outcome analysis of a prospective multicenter study. Int J Urol 2013;20:421-8.
5. Matsukawa Y, Takai S, Majima T, Funahashi Y, Kato M, Yamamoto T, et al. Two-year follow up of silodosin on lower urinary tract functions and symptoms in patients with benign prostatic hyperplasia based on prostate size: A prospective investigation using urodynamics. Ther Adv Urol 2018;10:263-72.
6. EAU Guidelines Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), Incl. Benign Prostatic Obstruction (BPO). Available from: https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-the-Management-of-Non-Neurogenic-Male-LUTS-2019.pdf. [Last accessed on 2020 Mar 05].
7. Tanuma Y, Tanaka Y, Takeyama K, Okamoto T. Does prostate volume affect the efficacy of α1D/A: Adrenoceptor antagonist naftopidil? Urol Ann 2016;8:20-5.
8. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003;167:530-7.
9. Lim KB, Ho H, Foo KT, Wong MY, Fook-Chong S. Comparison of intravesical prostatic protrusion, prostate volume and serum prostatic-specific antigen in the evaluation of bladder outlet obstruction. Int J Urol 2006;13:1509-13.
10. Chia SJ, Heng CT, Chan SP, Foo KT. Correlation of intravesical prostatic protrusion with bladder outlet obstruction. BJU Int 2003;91:371-4.
11. Shin SH, Kim JW, Kim JW, Oh MM, Moon du G. Defining the degree of intravesical prostatic protrusion in association with bladder outlet obstruction. Korean J Urol 2013;54:369-72.
12. Kim M, Cheeti A, Yoo C, Choo M, Paik JS, Oh SJ. Non-invasive clinical parameters for the prediction of urodynamic bladder outlet obstruction: Analysis using causal Bayesian networks. PLoS One 2014;9:e113131.
13. Trumbeckas D, Milonas D, Jievaltas M, Matjoseantis AJ, Kincius M,
Tanuma, et al.: PV cutoff level to predict efficacy

Grybas A, et al. Importance of prostate volume and urinary flow rate in prediction of bladder outlet obstruction in men with symptomatic benign prostatic hyperplasia. Cent European J Urol 2011;64:75-9.

14. Kaplan SA, Roehrborn CG, Hill LA, Volinn W. Effect of estimated prostate volume on silodosin-mediated improvements in the signs and symptoms of BPH: Does prostate size matter? Open Access J Urol 2011;3:89-93.

15. Masumori N, Tsukamoto T, Horita H, Sunaoshi K, Tanaka Y, Takeyama K, et al. Does baseline prostate volume affect the short-term outcome of tamsulosin? Low Urin Tract Symptoms 2014;6:113-6.

16. Park JS, Lee SW, Choi HY, Moon HS. The effects of tamsulosin dose escalation in benign prostate hyperplasia patients with lower urinary tract symptoms. Med Surg Urol 2012;5:1. [doi: 10.4172/2168-9857].

17. Hong KP, Byun YJ, Yoon H, Park YY, Chung WS. Prospective factor analysis of alpha blocker monotherapy failure in benign prostatic hyperplasia. Korean J Urol 2010;51:488-91.

18. Funahashi Y, Hattori R, Yoshino Y, Matsukawa Y, Sassa N, Gotoh M. Symptoms predictive for efficacy of naftopidil in patients with benign prostate hyperplasia. Low Urin Tract Symptoms 2011;3:113-7.

19. Yamaguchi S, Osanai H, Numata A, Watanabe M, Kakizaki H. α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: Efficacy of dose increase therapy. Int J Urol 2013;20:513-9.

20. Reynard JM, Abrams P. Bladder-outlet obstruction—Assessment of symptoms. World J Urol 1995;13:3-8.